Exenatide
BASIC2
AstraZeneca · Phase 3 · Active, not recruiting · Enrollment 63
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Exenatide once weekly extended-release | n/r | n/r | n/r | n/r |
| Matching placebo | n/r | n/r | n/r | n/r |
Not shown
- Exenatide once weekly extended-release: endpoint not reported
- Matching placebo: endpoint not reported